Sentinel node mapping and molecular staging in lung cancer

• DOI: 10.1200/jco.2004.22.90140.7191
• Publication Date: 2017-04-05T07:17:42Z
• Authors: D. Pulte; E. Li; B. Crawford; E. Newman; D. Mustalish; A. Alexander; D. R. Jacobson
• Keywords: Micrometastasis; Histology

7191 Background: Lymph node (LN) involvement predicts relapse in patients after resection of apparently localized nonsmall cell lung cancer (NSCLC). Molecular staging (MS) techniques can be used to detect micrometastatic disease, while sentinel lymph (SLN) mapping indicate which LNs are most likely contain micrometastases. Methods: We SLN and MS more sensitively LN RT-PCR for cytokeratin7 (CK7), a gene expressed normal malignant lung, but not LNs, was identify tumor-derived material LNs. Results: performed 13 during resection, 1–3 SLNs were identified each, sufficient RNA molecular studies obtained 12/13 patients. No major adverse reactions occurred. 11/12 the primary tumors CK7. 65 examined, including 21 from 11 evaluable Overall, 32/65 CK7+, 13/21 SLNs. 10/11 with had at least one CK7+ SLN. Routine histology showed T1N0-T2N0 disease 8 patients, T3N0 1 patient, N1 2 Of 9 N0 by routine histology, upstaged RT-PCR. All that positive RT-PCR-positive. Conclusions: is feasible NSCLC. identifies In this study, status predicted total all patients; there no “skip metastases.” This suggests study alone may MS, would make clinical setting. technique use stratifying into high (molecular N1) low N0) risk groups. Our results suggest micrometastasis pervasive resected NSCLC; true appears rare. significant financial relationships disclose.